Eli Lilly said on Monday it will let more patients apply for early access to retatrutide, expanding a special pathway for the unapproved obesity drug before FDA approval. The company said the access is still limited, but it is no longer confined to a single patient case.
The move puts Eli Lilly Retatrutide Early Access in the spotlight because the company is now inviting requests from health care providers after a report six weeks ago that it had granted special access to a single 79-year-old patient. For people searching today, the change answers the immediate question of whether the program is growing: it is, though only for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial.
That is the clearest detail Lilly has offered so far. A Lilly spokesperson said the company believes it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA guidance. The company also said it is actively reviewing requests from health care providers, which suggests the pathway is open in practice even if the gate remains narrow.
What Lilly has not said is how many patients will ultimately be approved. It also has not spelled out the medical criteria in public terms, leaving families and doctors to infer the boundaries of a program that had been mentioned only sparingly before now. The expansion broadens access, but it does not turn retatrutide into a general option for patients seeking a faster route around a clinical trial.
That matters because the person at the center of the earlier report was not an abstraction. The single 79-year-old patient received special access six weeks before Monday’s announcement, making the new policy look less like a sudden opening and more like a formalization of a pathway Lilly had already begun to use. The unanswered question now is not whether the company will consider requests. It is how many patients will clear the bar before the drug reaches FDA approval.
